Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 3,980.00
-10.00 (-0.25%)
May 29, 2026, 3:30 PM JST
Kaken Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 76,871 | 94,035 | 72,044 | 72,984 | 76,034 | |
Revenue Growth (YoY) | -18.25% | 30.52% | -1.29% | -4.01% | 1.41% |
Cost of Revenue | 36,879 | 35,502 | 33,505 | 33,428 | 34,458 |
Gross Profit | 39,992 | 58,533 | 38,539 | 39,556 | 41,576 |
Selling, General & Admin | 19,554 | 18,501 | 16,165 | 15,476 | 15,833 |
Research & Development | 20,585 | 18,725 | 12,543 | 15,789 | 8,420 |
Operating Expenses | 40,891 | 37,497 | 29,025 | 31,556 | 24,511 |
Operating Income | -899 | 21,036 | 9,514 | 8,000 | 17,065 |
Interest Expense | -45 | -28 | -17 | -17 | -17 |
Interest & Investment Income | 852 | 613 | 479 | 438 | 396 |
Currency Exchange Gain (Loss) | -166 | -370 | -59 | - | -31 |
Other Non Operating Income (Expenses) | 50 | 28 | 32 | 306 | 129 |
EBT Excluding Unusual Items | -208 | 21,279 | 9,949 | 8,727 | 17,542 |
Gain (Loss) on Sale of Investments | 2,014 | -287 | 13 | 1 | 1 |
Gain (Loss) on Sale of Assets | 1,366 | - | - | 1 | 195 |
Asset Writedown | -982 | -1,556 | -167 | -1,911 | -3,091 |
Other Unusual Items | 122 | -1 | - | -1 | -762 |
Pretax Income | 2,312 | 19,435 | 9,795 | 6,817 | 13,885 |
Income Tax Expense | 168 | 5,490 | 1,770 | 1,377 | 4,336 |
Net Income | 2,144 | 13,945 | 8,025 | 5,440 | 9,549 |
Net Income to Common | 2,144 | 13,945 | 8,025 | 5,440 | 9,549 |
Net Income Growth | -84.63% | 73.77% | 47.52% | -43.03% | -28.77% |
Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 |
Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 |
Shares Change (YoY) | -0.66% | 1.13% | 0.44% | -1.07% | -1.59% |
EPS (Basic) | 56.55 | 365.42 | 212.66 | 144.79 | 251.44 |
EPS (Diluted) | 56.55 | 365.42 | 212.66 | 144.79 | 251.44 |
EPS Growth | -84.52% | 71.83% | 46.87% | -42.41% | -27.62% |
Free Cash Flow | -14,075 | 25,642 | 716 | 7,266 | 10,350 |
Free Cash Flow Per Share | -371.26 | 671.92 | 18.97 | 193.39 | 272.53 |
Dividend Per Share | - | 150.000 | 150.000 | 150.000 | 150.000 |
Gross Margin | 52.02% | 62.25% | 53.49% | 54.20% | 54.68% |
Operating Margin | -1.17% | 22.37% | 13.21% | 10.96% | 22.44% |
Profit Margin | 2.79% | 14.83% | 11.14% | 7.45% | 12.56% |
Free Cash Flow Margin | -18.31% | 27.27% | 0.99% | 9.96% | 13.61% |
EBITDA | 2,426 | 23,590 | 12,267 | 10,568 | 19,551 |
EBITDA Margin | 3.16% | 25.09% | 17.03% | 14.48% | 25.71% |
D&A For EBITDA | 3,325 | 2,554 | 2,753 | 2,568 | 2,486 |
EBIT | -899 | 21,036 | 9,514 | 8,000 | 17,065 |
EBIT Margin | -1.17% | 22.37% | 13.21% | 10.96% | 22.44% |
Effective Tax Rate | 7.27% | 28.25% | 18.07% | 20.20% | 31.23% |